key: cord-0029935-t0brsgvo
authors: Stancil, Stephani L.; Tumberger, John; Strawn, Jeffrey R.
title: Target to treatment: A charge to develop biomarkers of response and tolerability in child and adolescent psychiatry
date: 2022-01-10
journal: Clin Transl Sci
DOI: 10.1111/cts.13216
sha: d36e5a2a7fa4625e51672266075020d03e9d5c61
doc_id: 29935
cord_uid: t0brsgvo

The current pediatric mental health crisis is characterized by staggering rates of depression, anxiety, and suicide. Beyond this, first‐line pharmacologic interventions for depressive and anxiety disorders in children and adolescents produce variable responses with two in five youths failing to respond. Given the heterogeneity of treatment response in pediatric depressive and anxiety disorders, pharmacodynamic biomarkers are necessary to develop precision therapeutics by identifying clear targets to guide treatment. This mini‐review summarizes candidate biomarkers and their development in pediatric mental health conditions. A framework for how these biomarkers may relate to safety, efficacy (e.g., surrogates for clinical endpoints), tolerability or target engagement (i.e., drug action) in children and adolescents is also presented. Taken together, accumulating data suggest that, in children and adolescents with myriad psychiatric disorders, pharmacodynamic biomarkers could facilitate developing drugs with well‐defined targets in specific populations, could inform treatment decisions, and hasten patients’ recovery.

The current pediatric mental health crisis is characterized by staggering rates of depression, anxiety, and suicide-now the second leading cause of death among children and young adults aged 10-24. 1 Whereas inadequate psychiatric resources, disparities in care, and limited evidence for many pharmacologic treatments for anxious and depressed youth fuel this crisis, the stress of a pandemic has further intensified this perilous situation. 2, 3 prescribing is the norm. 4 Beyond this, antidepressants with FDA-approvals for depressive and anxiety disorders (e.g., fluoxetine, escitalopram, and sertraline) produce variable responses and two in five adolescents fail to respond. 5 Clinical trials in children and adolescents with depressive and anxiety disorders frequently rely on unidimensional measures of overall symptom severity as the primary outcome. These measures generally use a linear combination (i.e., average or sum) of measurement across multiple symptom dimensions, which can be misleading. Beyond this, and high placebo response rates, 6 improvement in some symptoms may be more important for overall improvement than other symptoms, and symptoms can interact in complex ways. A related concern is that in certain youths who have "depression" or "anxiety," experience symptoms driven by exogenous factors-life struggles, adversity, and chronic variable stress-that boost scores on some measures. Thus, core symptoms may not drive these symptom ratings; rather, they may be driven by impairment. Finally, traditional approaches to identifying effective treatments for children and adolescents with mental health conditions are often mired by joint significance concerns related to efficacy and tolerability. 7 Yet, response (i.e., efficacy) is inherently linked to tolerability and vice versa, but the joint model of both variables needed to account for their interaction are rare in clinical psychopharmacologic treatment trials in youths. These issues complicate the interpretation of these studies and lead us to abandon potentially effective interventions.

Children and adolescents who are lucky enough to respond to medication often enjoy functional recovery; however, response can take months. Delayed responsewhich is common for antidepressant medications in children and adolescents-relates, in part, to pharmacodynamic processes (e.g., activation of second messenger systems and gene expression). Children, adolescents, and their families deserve precision therapeutics in pediatric mental health-an approach that identifies who will respond to what medication, at what dose the first time.

Objective biomarkers of response (i.e., pharmacodynamic biomarkers) are critical to developing precision therapeutics; they hold the potential to identify clear targets to guide treatment. These biomarkers may speak to safety, efficacy (e.g., surrogate for clinical end point or how a patient feels or functions), tolerability, or target engagement (i.e., drug action). 8 Pharmacodynamic biomarkers can be leveraged for both drug development and repurposing ( Figure 1 ); they can be employed to demonstrate quantifiable response and facilitate successful trials through processes, such as sample stratification (e.g., enrichment with those who demonstrate evidence of target engagement or pathway modulation), exposure optimization, and dose finding. For psychotropic medications, pharmacodynamic biomarkers are urgently needed to identify subgroups that are more likely to respond (or not respond) and at what exposure early in drug development (e.g., exposure optimization). This could focus drug development efforts on a targeted group that is more likely to respond and, at the same time, identify patients that are less likely to respond at a given exposure (e.g., due to genetic variability leading to reduced receptor expression) who may benefit from alternative treatments or dosing schemes or who may have a distinct disease phenotype. Pharmacodynamic biomarkers that predict clinical outcomes can be used to target treatment and may function similarly to predictive or prognostic biomarkers. 8 Given the heterogeneity of depressive and anxiety disorders and the common use of self-reported symptom monitoring, which is complicated by recall bias, pharmacodynamic biomarkers are necessary to advance mental health therapeutics for children and adolescents. This mini-review describes how we might qualify pharmacodynamic biomarkers in child and adolescent psychiatry to (1) aid in drug development and repurposing and (2) to improve the therapeutic landscape.

The development of pharmacodynamic biomarkers must be rigorous to ensure the quality and strength of evidence supports the context of use. Below, we pose four questions that must be answered as we develop pharmacodynamic biomarkers in child and adolescent psychiatry. Examples from pediatric pharmacodynamic biomarker studies are used preferentially, when available, to illustrate our points. However, due to the dearth of pediatric data, examples from adults are also included.

First, we must identify the objective of pharmacodynamic biomarker development. Is the pharmacodynamic biomarker intended to support drug approval or labelling decisions? Will it serve as the primary end point or surrogate end point (i.e., intended to substitute for a clinical outcome)? If intended to support regulatory decisions, formal qualification of the pharmacodynamic biomarker should be considered. Biomarker qualification is a formal, complex and iterative process which requires input from multiple stakeholders (e.g., sponsors and regulatory agencies). The FDA has provided guidance for biomarker qualification 9 and various groups have reviews describing the process of integrating regulatory guidance (e.g., the FDA and European Medicines Agency [EMA]) into biomarker development. 10 The qualification process may be initiated by an individual, a sponsor, or consortia who then bears the burden of risk. An investigator may study a pharmacodynamic biomarker for a single compound, find the data to be promising, and then generate interest within a consortium for further development with related compounds. Biomarker qualification leads to a spectrum of outcomes, from integration in the drug development process to involvement in approval decisions and inclusion in labeling. Unfortunately, there is yet to be a qualified pharmacodynamic biomarker for mental health treatment.

The use of lactate infusion to probe benzodiazepine response in CO 2 -sensitive panic disorder serves as an example of a potential pharmacodynamic biomarker that stopped short of formal qualification. Table 1 lists this and other potential pharmacodynamic biomarkers that require additional study.

If formal qualification is not desired or cannot be achieved due to limited evidence, an investigator may seek guidance from the FDA to gain insight or garner support that a promising biomarker warrants continued study from a regulatory perspective.

Answering this question requires determining the "context of use," which defines what will be detected in the clinical population of interest and will dictate the type of studies required to provide adequate evidence. The context of use should be grounded in a biological rationale that is shared between the mechanism of action of the drug and pharmacodynamic biomarker. As an example, Javitt et al. recently evaluated functional magnetic

The potential of pharmacodynamic biomarkers to aid in drug development, repurposing, and precision therapeutics in children and adolescents T A B L E 1 Potential PD biomarkers in pediatric and adolescent psychotropic drug development resonance imaging (fMRI) as a pharmacodynamic biomarker of glutaminergic "functional target engagement" for early phase drug trials (Table 1 ). Blood oxygen leveldependent response, thought to be partially dependent on glutamate release, was detected after ketamine (i.e., glutaminergic MOA) and placebo in a prespecified region (i.e., midcingulate cortex) thus detecting functional target engagement or, perhaps more precisely, glutaminergic pathway modulation.

Another example is the use of fMRI to detect reward response in eating disorders. Frank et al. quantified predictive error reward response in prespecified regions of interest and demonstrated exaggerated reward response (i.e., positive predictive error) in restrictive eating disorders and diminished reward response (i.e., negative predictive error) in those with binge-based eating disorder. Whether this biomarker could detect pharmacodynamic response is yet to be investigated. It is plausible Potential pharmacodynamic biomarkers that may also serve as predictive biomarkers based on the purpose of the primary study.

T A B L E 1 (Continued) that reward system modulation by opioid antagonism would be detected given both the drug and predictive error detected by fMRI interface with an opioid reward mechanism. 11 Quantitative electroencephalogram (qEEG) has been explored as a pharmacodynamic biomarker in pediatric attention deficit hyperactivity disorder (ADHD) treatment and appears responsive to stimulant medication (Table 1) . However, controlled studies with a clear and consistent context of use are lacking. Future studies should identify the optimal qEEG measure (e.g., theta/beta ratio), connect the biological rationale of the measure with the medication mechanism of action, and determine a relevant outcome (e.g., identifying methylphenidate vs. amphetamine responder).

In other words, what evidence is needed to ensure the pharmacodynamic biomarker measures what its intended to measure? The extent of validation will depend, in part, on the answers to the above questions, particularly the context of use. Mirroring the analytical method validation process for drugs, elements such as sensitivity, specificity, reproducibility, and reliability should be considered and intentionally tested. Sources of biological variability (e.g., genetic, metabolomic) should also be defined and explained, if possible. As an example of reproducibility and reliability, the study design utilized by Javitt et al. to develop a pharmacodynamic biomarker of glutaminergic target engagement included a multisite neuroimaging feasibility evaluation. This is important given multisite trials are inherent in many drug-development programs and evidence of biomarker consistency across sites, particularly for neuroimaging, is necessary.

Additional considerations for qEEG as a pharmacodynamic biomarker include the development and study of consistent protocols that control conditions such as eye position (i.e., open or closed), sleep deprivation, number of electrodes, and task versus resting state.

Pharmacodynamic biomarkers may or may not correspond with a clinical outcome based on the available evidence or proposed context of use. At a minimum, pharmacodynamic biomarkers should detect target engagement, pathway modulation, or a disease-related change involving the drug mechanism of action. A recent randomized controlled trial of escitalopram in adolescents with generalized anxiety disorder utilized functional connectivity detected by resting state MRI to show that early functional connectivity changes (e.g., 2 weeks post-treatment) predicted clinical improvement in anxiety symptoms at 8 weeks (Table 1 ). If replicated, this biomarker, serving both pharmacodynamic and predictive purposes, could shave weeks off the response time for many patients that results from delays in switching medication later in treatment. This is particularly important given that randomized controlled trials of adolescents with depression reveal that early response and early changes in interventions are associated with greater improvement compared to delayed changes in treatments. 12 Taking the above eating disorder example from Frank et al. a step further, longitudinal studies may be designed to understand how well fMRI-determined reward response upon acute treatment with reward modulating medications (e.g., opioid antagonists) predicts remission or symptom burden. 11 Clearly, this work may take years to establish and better therapeutics are urgently needed.

In the interim, the pharmacodynamic biomarker could potentially serve as a reasonably likely surrogate end point for a clinical outcome, meaning it detects an effect that is expected, but not established to have clinical benefit. 8 One example of work in progress is the identification of synaptic alterations by positron emission tomography (PET). Evidence suggests that reduced synaptic density throughout the brain may be seen in individuals with major depressive disorder. 13 Synaptic alterations may represent a surrogate for functional deficits and symptoms, but further work is needed to establish the connection. The glutaminergic agent, ketamine, increases synaptogenesis in a murine model. Whether ketamine produces the same effect in humans is yet to be determined; however, the development of PET as a biomarker of synaptic alterations may elucidate mechanisms of action for ketamine's antidepressive effects and provide a tool for facilitate novel therapeutic approaches.

For pediatric mental health disorders, identifying the "gold standard" clinical outcome for which to establish clinical validity requires multidisciplinary discourse, particularly given our understanding of the limitations of self-report clinical assessment tools.

To combat the pediatric mental health crisis and reduce rates of death and disability that result from ineffective treatment, we must develop better therapeutics and use existing therapeutics with more precision.

Pharmacodynamic biomarkers could allow us to reimagine the therapeutic landscape. These biomarkers could hasten the development of drugs with well-defined targets in specific populations, inform treatment decisions, and potentially restore functioning and decrease distress more quickly. However, developing these pharmacodynamic biomarkers requires analytic validity and a process that is mechanistically and clinically informed and carefully considers the context of use. We have briefly reviewed potential pharmacodynamic biomarkers and specific considerations to foster thought, facilitate identifying clear targets, and furthering the development of promising options in child and adolescent psychiatry. The time to act is now.

Dr. Strawn has received research support from AbbVie, PCORI, and the National Institutes of Health. He has provided consultation to Intracellular Therapeutics and the FDA. He receives royalties from Springer Publishing and UpToDate and received material support from Myriad. He has also received honoraria from CMEology, Genomind, Neuroscience Education Institute, the American Academy of Pediatrics, and the American Academy of Child and Adolescent Psychiatry. All other authors declared no competing interests for this work.

As an Editor-in-Training for Clinical and Translational Science, Stephani Stancil was not involved in the review or decision process for this paper.

Mental health-related emergency department visits among children aged <18 years during the COVID-19 pandemic -United States

Children's mental health emergency department visits

Trends in antipsychotic medication use in young privately insured children

Research review: Pediatric anxiety disorders -what have we learnt in the last 10 years?

The impact of failed antidepressant trials on outcomes in children and adolescents with anxiety and depression: a systematic review and meta-analysis

Switching selective serotonin reuptake inhibitors in adolescents with selective serotonin reuptake inhibitor-resistant major depressive disorder: balancing tolerability and efficacy

BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Food and Drug Administration (US)

Biomarker Qualification: Evidentiary Framework

Biomarkers: opportunities and challenges for drug development in the current regulatory landscape

Association of brain reward response with body mass index and ventral striatal-hypothalamic circuitry among young women with eating disorders

Critical decision points for augmenting interpersonal psychotherapy for depressed adolescents: a pilot sequential multiple assignment randomized trial

First in vivo evaluations of synaptic density alterations in the brain

Acid-base dysregulation and chemosensory mechanisms in panic disorder: a translational update

Platelet serotonin transporter in depressed children and adolescents: 3H-paroxetine platelet binding before and after sertraline

Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis

Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

Serotonin transport kinetics correlated between human platelets and brain synaptosomes

Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation

The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET

The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study

Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial

Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder

Behavioral and electrophysiologic predictors of treatment response to stimulants in children with attention disorders

Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test

Medication effects on EEG biomarkers in attention-deficit/hyperactivity disorder

Predicting clinical gains and side effects of stimulant medication in pediatric attention-deficit/hyperactivity disorder by combining measures from qEEG and ERPs in a Cued GO/NOGO Task

Acute neurofunctional effects of escitalopram in pediatric anxiety: a double-blind, placebo-controlled trial

Emotion-related network reorganization following fish oil supplementation in depressed bipolar offspring: an fMRI graph-based connectome analysis

Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial

Evidence for increased glutamatergic cortical facilitation in children and adolescents with major depressive disorder

Cortical inhibitory and excitatory correlates of depression severity in children and adolescents

Transcranial magnetic stimulation markers of antidepressant treatment in adolescents with major depressive disorder

Motor cortex excitability and inhibitory imbalance in autism spectrum disorder assessed with transcranial magnetic stimulation: a systematic review

A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans

Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery

A study of novel exploratory tools, digital technologies, and central nervous system biomarkers to characterize unipolar depression. Front Psychiatry

Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study

Neurochemical effects of quetiapine in patients with bipolar mania: a proton magnetic resonance spectroscopy study

Neurochemical effects of olanzapine in firsthospitalization manic adolescents: a proton magnetic resonance spectroscopy study

Variation in rostral anterior cingulate functional connectivity with amygdala and caudate during first manic episode distinguish bipolar young adults who do not remit following treatment

Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, doseranging, functional magnetic resonance imaging study